A Revolutionary Road Map for Obesity Management and Beyond: Tirzepatide as a Dual-Acting Insulinotropic Polypeptide
Tirzepatide is a revolutionary and promising medication with a high impact in the treatment of Obesity and T2DM with their complications. Its efficacy was proven through different trials in achieving favorable weight loss and a significant reduction in glycemic index. It also treated a large diversity of related co-morbidities, including fatty liver, cardiovascular disease, dyslipidemia, and more. Tirzepatide is well tolerated, has a good safety profile, and is highly reliable and suitable for use in a population.
Authors
- Saad M. Mahmoud (ORCID: https://orcid.org/0009-0001-5553-729X)
- Maysaa Abdulla (ORCID: https://orcid.org/0000-0002-0766-0656)
- Asgad Abdalgbar
- Laith Thamer Al-Ameri (ORCID: https://orcid.org/0000-0002-5863-1564)
- Ekhlas Khalid Hameed (ORCID: https://orcid.org/0000-0002-0068-3329)
- Nada Faisal Al-Dulaimi
- Ziyad Dulaimi
- May Yousif Wahdan
- Ali Al Joboory
- Luay Alshara
Institutions
- Uppsala University (SE)
- The Royal Melbourne Hospital (AU)
- Royal Columbian Hospital (CA)
- University of Baghdad (IQ)
- Cornell University (US)
- Omar Al-Mukhtar University (LY)
- Presbyterian Hospital (US)
- Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
Publication Details
- Journal
- AL-Kindy College Medical Journal
- Published
- 2024-12-01
- DOI
- https://doi.org/10.47723/hesy7z38
- Citations
- 3
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.34
Funders
- University of Baghdad